Veristat Executive and Leadership Team

Kim McLean Boericke, the Chief Executive Officer at Veristat, directs the overarching strategic vision for this science-focused clinical research organization. Overseeing the integration of complex clinical trial services, the Chief Executive Officer ensures that pharmaceutical and biotechnology partners receive high-quality regulatory support. Kim McLean Boericke drives the expansion of service capabilities across North American and international markets, focusing on the successful delivery of medical device development programs. By aligning internal research teams with evolving industry standards, the Chief Executive Officer maintains the competitive edge of the firm. This leadership role involves constant collaboration with the Board to optimize operational efficiency and long-term growth. Through the implementation of advanced data-driven methodologies, the Chief Executive Officer secures the reputation of the company as a premier partner in global health innovation. Boericke consistently monitors market trends to adapt service offerings for diverse client needs.

David Koster, the Co-Founder & Chief Executive Officer at Veristat, architects the foundational business model and long-term corporate development strategy. Focusing on the evolution of the organization from a boutique research firm to a full-service clinical partner, the Co-Founder & Chief Executive Officer manages high-level partnerships with global medical device and pharmaceutical entities. David Koster drives the pursuit of excellence in regulatory submissions, ensuring that every clinical trial meets stringent international compliance requirements. By fostering a culture of scientific rigor, the Co-Founder & Chief Executive Officer supports the development of life-saving therapies. This role requires constant engagement with industry stakeholders to identify emerging opportunities for service expansion. Koster oversees the strategic direction of the company, ensuring that the mission of accelerating clinical research remains the primary focus. Through disciplined leadership, the Co-Founder & Chief Executive Officer sustains the growth trajectory of the firm across diverse therapeutic areas.

Joshua Korth, the Chief Financial Officer at Veristat, manages the fiscal health and capital allocation strategies for this clinical research organization. Overseeing the financial planning and analysis departments, the Chief Financial Officer ensures that resources support the scaling of clinical trial operations and regulatory service delivery. Joshua Korth drives the financial modeling required for international expansion, providing the necessary stability for the company to invest in advanced research technologies. By collaborating with the executive team, the Chief Financial Officer aligns budgetary priorities with the strategic goals of the firm. This leadership role involves rigorous oversight of financial reporting and risk management to protect the interests of stakeholders. Korth maintains the financial infrastructure that allows the organization to support complex biotechnology projects effectively. Through precise fiscal management, the Chief Financial Officer enables the company to maintain its position as a leader in the competitive clinical research landscape.

John Blaser, the President at Veristat, executes the daily operational strategy and manages the delivery of clinical research services. Overseeing the functional departments responsible for trial execution and regulatory documentation, the President ensures that all client projects adhere to the highest scientific standards. John Blaser drives the operational efficiency of the firm, focusing on the seamless integration of data management and biostatistics for pharmaceutical and medical device clients. By coordinating across internal teams, the President facilitates the successful completion of complex regulatory submissions. This leadership role involves direct oversight of service quality and client satisfaction metrics. Blaser maintains the operational framework that allows the company to handle diverse clinical trials across multiple geographic regions. Through the implementation of standardized processes, the President supports the overall mission of accelerating the development of new medical treatments. Blaser ensures that the organization remains agile in a rapidly changing clinical research environment.